Latest Teriparatide Stories
INDIANAPOLIS, July 23 /PRNewswire-FirstCall/ -- Today, Eli Lilly and Company (NYSE: LLY) announced that the U.S.
Bone fractures might heal faster if the patient is injected with medications. This is the outcome of a unique study of 102 women with wrist fractures.
Denosumab and Forteo/Forsteo Will Each Achieve Blockbuster Status in 2018, According to a New Report from Decision Resources WALTHAM, Mass., June 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen's novel agent denosumab and Eli Lilly's parathyroid hormone (PTH) analogue Forteo/Forsteo (teriparatide) will drive robust 4.3 percent annual growth in the osteoporosis drug market from 2013 to 2018...
A drug approved for the treatment of osteoporosis is healing broken bones with stem cells.
In-body stem cell therapy has enormous potential for bone injuries.
COLLEGEVILLE, Pa., Feb.
BEDFORD, Mass., Jan. 6 /PRNewswire/ -- MicroCHIPS, Inc., a developer of intelligent implanted devices, has named Massachusetts General Hospital endocrinologist, Robert M. Neer, MD, to its Scientific Advisory Board.
Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology, today announced positive results from its phase 2, randomized, multi-center, double-blind, multi-dose study designed to determine safety and efficacy of its ZP-PTH rapid delivery patch for the treatment of osteoporosis.
Eli Lilly and Company has announced that its new Forteo delivery device is available for patient use in the US. The new delivery device was designed specifically for Forteo patients to help them more easily administer their treatment on a day-to-day basis, the company said.
INDIANAPOLIS, Oct. 15 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced that its new, simpler-to-use FORTEO Delivery Device is available for patient use in the United States.
- A serpent whose bite was fabled to produce intense thirst.